Comparative effectiveness and safety of five leading new-generation TAVI devices: 12-month results from the RISPEVA Study

被引：0

作者：

Giordano, Arturo ^{[1
]}

Biondi-Zoccai, Giuseppe ^{[2
]}

Corcione, Nicola ^{[3
]}

Ferraro, Paolo ^{[1
]}

Bedogni, Francesco ^{[4
]}

Testa, Luca ^{[5
]}

Sardella, Gennaro ^{[6
]}

Mancone, Massimo ^{[7
]}

Tomai, Fabrizio ^{[8
]}

De Persio, Giovanni ^{[9
]}

Iadanza, Alessandro ^{[10
]}

Pierli, Carlo ^{[11
]}

Frati, Giacomo ^{[7
]}

机构：

[1] Pineta Grande Hosp, Castel Volturno, Caserta, Italy

[2] Sapienza Univ Rome, Rome, Italy

[3] Presidio Osped Pineta Grande, Castel Volturno, Caserta, Italy

[4] Policlin San Donato, Milan, Italy

[5] IRCCS San Donato Hosp, Milan, Italy

[6] Policlin Umberto I Univ, Rome, Italy

[7] Sapienza Univ Rome, Rome, Italy

[8] European Hosp, Rome, Italy

[9] European Hosp, Rome, Italy

[10] Azienda Osped Univ, Le Scotte Hosp, Siena, Italy

[11] Le Scotte Hosp, Siena, Italy

来源：

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2018年 / 72卷 / 13期

关键词：

D O I：

10.1016/j.jacc.2018.08.1128

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

TCT-44

引用

页码：B19 / B20

页数：2

共 50 条

[31] Clinical effectiveness, safety and immunogenicity of anti-TNF therapy in Crohn's disease: 12-month data from the PANTS study
Kennedy, N. A.
Heap, G.
Hamilton, B.
Walker, G. J.
Bewshea, C.
Bouri, S.
Goodhand, J.
Ahmad, T.
JOURNAL OF CROHNS & COLITIS, 2018, 12 : S21 - S22
[32] Comparative safety and ocular hypotensive efficacy of brimonidine tartrate 0.2% and timolol maleate 0.5% in patients with glaucoma or ocular hypertension: 12-month results from an ongoing study
Lewis, RA
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1997, 38 (04) : 1149 - 1149
[33] Safety and Effectiveness of the Endeavor Zotarolimus-Eluting Stent in Real-World Clinical Practice 12-Month Data From the E-Five Registry
Lotan, Chaim
Meredith, Ian T.
Mauri, Laura
Liu, Minglei
Rothman, Martin T.
JACC-CARDIOVASCULAR INTERVENTIONS, 2009, 2 (12) : 1227 - 1235
[34] Frovatriptan for the prevention of menstrual migraine headaches: Results of a 12-month open-label safety and tolerability study
Gammaitoni, A
Ford, C
Tobin, J
Shaw, R
Campbell, J
NEUROLOGY, 2006, 66 (05) : A224 - A224
[35] Endeavor I "first in human" safety and efficacy study - 12-month clinical, angiographic, and intravascular ultrasound results
Meredith, IT
Ormiston, J
Whitbourn, R
Kay, P
Muller, D
Popma, JJ
Fitzgerald, P
Kuntz, RE
CIRCULATION, 2004, 110 (17) : 563 - 564
[36] 12-Month Results from the Multicenter LOCOMOTIVE Study: Should We All Jump on this Bandwagon?
van den Berg, Jos C.
CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 2019, 42 (02) : 176 - 177
[37] Defining And Predicting Adherence To An Online Lifestyle Program: 12-month Results From The Ocelot Study
Conroy, Margaret B.
Bhargava, Tina
Tudorascu, Dana
Karpov, Irina
Knight-Sepulveda, Karina
Hess, Rachel
Fischer, Gary S.
Simkin-Silverman, Laurey
McTigue, Kathleen M.
MEDICINE AND SCIENCE IN SPORTS AND EXERCISE, 2013, 45 (05): : 382 - 382
[38] 12-Month Results from the Multicenter LOCOMOTIVE Study: Should We All Jump on this Bandwagon?
Jos C. van den Berg
CardioVascular and Interventional Radiology, 2019, 42 : 176 - 177
[39] Safety and effectiveness of the Catania Polyzene-F coated stent in real world clinical practice: 12-month results from the ATLANTA 2 registry
Tamburino, Corrado
Capodanno, Davide
Di Salvo, Maria Elena
Sanfilippo, Alessandra
Cascone, Irene
Incardona, Valentina
Longo, Giovanni
Giacoppo, Daniele
Capranzano, Piera
Sgroi, Carmelo
Ussia, Gianpaolo
Monaco, Alfio
La Manna, Alessio
EUROINTERVENTION, 2012, 7 (09) : 1062 - 1068
[40] Results from a 12-month open-label safety study of lumateperone (ITI-007) in patients with stable symptoms of schizophrenia
Correll, C. U.
Vanover, K. E.
Durgam, S.
Weingart, M.
Davis, R.
Satlin, A.
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : S455 - S456

← 1 2 3 4 5 →